Benjamin Wolozin completed his undergraduate education at Wesleyan University in Middletown, CT. He earned his M.D. and Ph.D. degrees from Albert Einstein College of Medicine, as part of the Medical Scientist Training Program. His postdoctoral fellowships were spent at Mt. Sinai Medical Center (1988-9) and the National Institute of Mental Health (1989–96). He joined Loyola University Medical Center in 1996 as an Associate Professor and rose to the rank of tenured full professor. He joined the Boston University School of Medicine’s Department of Pharmacology in 2004 as a Professor and is currently obtaining an adjunct position in the Dept. of Neurology. His interests focus on the pathophysiology of neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease and Amyotrophic Lateral Sclerosis. His work on Alzheimer’s disease examines the role of cholesterol in the pathophysiology of Alzheimer’s disease, and stems from his discovery in 2000 that subjects taking the cholesterol-lowering medicines, termed statins, have a lower incidence of Alzheimer’s disease. His work on Parkinson’s disease examines the interaction between genes implicated in the disease, such as LRRK2 and alpha-synuclein, and environmental factors implicated in the disease. His work on ALS focuses on the response of RNA metabolism and protein translation to stress. He uses multiple approaches to study neurodegenerative disease, ranging from molecular approaches to epidemiology. These approaches include molecular biology, cellular biology, transgenic mice, transgenic C. elegans, study of human brain samples and epidemiological database analyses.